- All Journals
- Al-Qadisiyah University
- Basrah University
- Kirkuk University
- Mosul University
- The Iraqi Borad for Medical Specialization
- University of Anbar
- University of Technology
- Al Mustafa University
- Al-Zahraa University for Women
- Alnoor University
- Kunooz University
- Misan University
- Ninevah University
- Tikrit University
- University of Al-Hamdaniya
- University of Kerbala
Metabolic Syndrome and Cardiovascular Risk Profiles in Female Patients with Hashimoto’s Thyroiditis | ||
| Al- Anbar Medical Journal | ||
| Volume 22, Issue 1, January 2026, Pages 27-33 PDF (1.77 M) | ||
| Document Type: Original articles | ||
| DOI: 10.33091/amj.2025.161992.2309 | ||
| Authors | ||
| Noor alhuda Saber Alkhazrajy* ; Dhifaf Zeki Aziz | ||
| Department of Pathological Analyses, Faculty of Science, University of Kufa, Al-Najaf, Iraq. | ||
| Abstract | ||
| Background: Hashimoto’s thyroiditis (HT) is a common autoimmune disease, especially in females. While hypothyroidism is a recognized complication, emerging evidence links HT to metabolic disturbances and increased cardiovascular risk. However, the broader systemic effects in untreated patients remain insufficiently clarified. Objectives: To assess the metabolic and cardiovascular risk profiles among women with HT, with a special emphasis on lipid parameters, insulin resistance (IR), and inflammation. Materials and Methods: This case-control study included 100 women: 50 patients with HT (25 newly diagnosed and untreated, and 25 receiving thyroid hormone replacement therapy) and 50 age-matched healthy controls. Anthropometric measures, glycemic status, lipid profile, and inflammatory markers were assessed. The evaluated indices included HOMA-IR, triglyceride/HDL-C ratio, LDL-C/HDL-C ratio, Atherogenic Index of Plasma, Lipid Comprehensive Index, and high-sensitivity C-reactive protein. Results: Patients with HT had significantly greater body mass index, fasting glucose, fasting triglyceride, LDL-C, IR, and markers of inflammation than controls (all P-values < 0.001). Atherogenic risk, as measured by both AIP and LCI, was significantly elevated in greater than 90% of patients with HT, with the highest burden among untreated patients. While thyroid hormone therapy produced a degree of improvement, a number of cardiometabolic risk factors persisted at elevated levels. Conclusion: Female patients with HT frequently exhibit adverse metabolic and cardiovascular alterations, likely driven by chronic inflammation and thyroid dysfunction. Early screening and comprehensive management are essential, particularly for newly diagnosed and untreated women with HT. | ||
| Keywords | ||
| Hashimoto thyroiditis, Cardiovascular disease; Insulin resistance; Lipid indices; Metabolic syndrome | ||
| References | ||
|
[1] J. Li et al., "Thyroid antibodies in Hashimoto’s thyroiditis patients are positively associated with inflammation and multiple symptoms," Scientific Reports, vol. 14, no. 1, p. 27902, 2024.
[2] T. S. Saeed Al-Rawi, N. S. Shamkhi, and N. S. Haddad, "Association of Anti-Thyroglobulin and Anti-Thyroid Peroxidase Antibodies in Patients with Primary Hypothyroidism," Al-Anbar Medical Journal, vol. 19, no. 2, pp. 141–147, 2023.
[3] A. Patrizio et al., "Hypothyroidism and metabolic cardiovascular disease," Frontiers in endocrinology, vol. 15, p. 1408684, 2024.
[4] A. Pingitore, M. Gaggini, F. Mastorci, L. Sabatino, L. Cordiviola, and C. Vassalle, "Metabolic syndrome, thyroid dysfunction, and cardiovascular risk: the triptych of evil," International Journal of Molecular Sciences, vol. 25, no. 19, p. 10628, 2024.
[5] J. S. Mammen and A. R. Cappola, "Autoimmune thyroid disease in women," Jama, vol. 325, no. 23, pp. 2392-2393, 2021.
[6] A. Khan, N. Shah, and M. Thakkar, "Study of clinical profile of hypothyroidism with emphasis on vitamin B12 levels," HEADACHE, vol. 28, p. 37.33, 2019.
[7] O. de la Brassinne Bonardeaux, M. Deneye, C. Oury, M. Moonen, and P. Lancellotti, "High-Sensitivity CRP and Occurrence of Cancer in Cardiovascular Disease Patients with Cardiovascular," Journal of Clinical Medicine, vol. 14, no. 4, p. 1193, 2025.
[8] B. K. Jha et al., "Association of Metabolic Syndrome with Increased Cardiovascular Risk in Hypothyroidism Patients: Evidence from a Nepalese Population," Journal of Manmohan Memorial Institute of Health Sciences, vol. 10, no. 1, pp. 58-61, 2025.
[9] D. S. Elgendy, M. M. Abdelraof, E. A. Galbat, and M. M. Abdalraouf, "Cardiovascular Risk Factors in Patients with Chronic Autoimmune Thyroiditis," International journal of health sciences, vol. 6, no. S5, pp. 4347-4355, 2022.
[10] E. Berta et al., "Hypertension in thyroid disorders," Frontiers in endocrinology, vol. 10, p. 482, 2019.
[11] J.-L. Song et al., "Association of thyroid autoimmunity with extra-thyroid diseases and the risk of mortality among adults: evidence from the NHANES," Frontiers in Endocrinology, vol. 15, p. 1323994, 2024.
[12] R. A. H. Ali, N. A. Mahana, A. A. H. Mahdi, D. S. Wahb, A. Bakr, and A. M. Badr, "Anti-TPO and anti-TSHR antibodies in combination with T3, T4, and TSH exhibited a diagnostic curve for Hashimoto patients," The Journal of Basic and Applied Zoology, vol. 86, no. 1, p. 32, 2025.
[13] C. Mele et al., "The pattern of TSH and fT4 levels across different BMI ranges in a large cohort of euthyroid patients with obesity," Frontiers in Endocrinology, vol. 13, p. 1029376, 2022.
[14] S. Khan, A. Siddiqa, M. Rafiq, N. Fayyaz, M. A. Asghar, and R. Hafeez, "Gender effect on anti TPO antibodies and hypothyroidism in patients presenting to a teaching hospital, Bahawalpur, Pakistan," The Professional Medical Journal, vol. 29, no. 09, pp. 1379-1383, 2022.
[15] L. Ostrowska, D. Gier, and B. Zyśk, "The influence of reducing diets on changes in thyroid parameters in women suffering from obesity and Hashimoto’s disease," Nutrients, vol. 13, no. 3, p. 862, 2021.
[16] L. Mehran, N. Delbari, A. Amouzegar, M. Hasheminia, M. Tohidi, and F. Azizi, "Reduced sensitivity to thyroid hormone is associated with diabetes and hypertension," The Journal of Clinical Endocrinology & Metabolism, vol. 107, no. 1, pp. 167-176, 2022.
[17] M. Gierach, J. Gierach, and R. Junik, "Insulin resistance and thyroid disorders," Endokrynologia Polska, vol. 65, no. 1, pp. 70-76, 2014.
[18] F. Comas et al., "Adipose tissue TSH as a new modulator of human adipocyte mitochondrial function," International Journal of Obesity, vol. 43, no. 8, pp. 1611-1619, 2019.
[19] C. J. Packard, "Remnants, LDL, and the quantification of lipoprotein-associated risk in atherosclerotic cardiovascular disease," Current atherosclerosis reports, vol. 24, no. 3, pp. 133-142, 2022.
[20] E. Wieczorek, A. Ćwiklińska, A. Kuchta, B. Kortas-Stempak, A. Gliwińska, and M. Jankowski, "The differential effects of HDL subpopulations on lipoprotein lipase (LPL)-mediated VLDL catabolism," Biomedicines, vol. 9, no. 12, p. 1839, 2021.
[21] H. Cengiz, T. Demirci, C. Varim, and A. Tamer, "The effect of thyroid autoimmunity on dyslipidemia in patients with euthyroid hashimoto thyroiditis," Pakistan Journal of Medical Sciences, vol. 37, no. 5, p. 1365, 2021.
[22] H. Liu and D. Peng, "Update on dyslipidemia in hypothyroidism: the mechanism of dyslipidemia in hypothyroidism," Endocrine Connections, vol. 11, no. 2, e210002, 2022.
[23] E. Malczyk, J. Wyka, and A. Malczyk, "Body composition and Hashimoto disease," Roczniki Państwowego Zakładu Higieny, vol. 72, no. 4, pp. 345-352, 2021.
[24] H. Alwan, V. A. Ribero, O. Efthimiou, C. Del Giovane, N. Rodondi, and L. Duntas, "A systematic review and meta-analysis investigating the relationship between metabolic syndrome and the incidence of thyroid diseases," Endocrine, vol. 84, no. 2, pp. 320-327, 2024.
[25] J. D. Horton, J. A. Cuthbert, and D. K. Spady, "Dietary fatty acids regulate hepatic low density lipoprotein (LDL) transport by altering LDL receptor protein and mRNA levels," The Journal of clinical investigation, vol. 92, no. 2, pp. 743-749, 1993.
[26] M. Khazaal, "Concise Review of Common Non-Traditional Dyslipidemic Indices in Clinical Practice," AlQalam Journal of Medical and Applied Sciences, vol 6, issue 2, pp. 395-400, 2023.
[27] Y. B. Araújo, A. B. R. Almeida, M. F. M. Viana, and R. A. Meneguz-Moreno, "Use of atherogenic indices as assessment methods of clinical atherosclerotic diseases," Arquivos Brasileiros De Cardiologia, vol. 120, p. e20230418, 2023.
| ||
|
Statistics Article View: 533 PDF Download: 293 |
||